EUVIMEDEUVIMED entdecken
Multizentrische Studie

Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study

Kenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, Kensaku Ishihara, Naoki Inoue, Keita Izumi, Motohiro Fujiwara, Masahiro Toide, Takanobu Yamamoto, Sho Uehara, Saori Araki, Masaharu Inoue und 6 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02563-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Kenji Tanabe und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHumansMaleFemaleAgedRetrospective StudiesMiddle AgedPrognosisAged, 80 and overDrug Resistance, NeoplasmAdultBiomarkers, TumorAntineoplastic Agents, ImmunologicalProgression-Free SurvivalCarcinoma, Transitional CellUrologic NeoplasmsUrinary Bladder NeoplasmsNeutrophils

Stichwörter der Autor:innen

Immune checkpoint inhibitorsMetastasisPrognosisTransitional cell carcinoma

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedBiomarkers, TumorAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan.
  • Department of Urology, Saitama Red Cross Hospital, 1-5 Shintoshin, Chuo-ku, Saitama, 330-8553, Japan. shu_kobayashi@saitama-med.jrc.or.jp.
  • Department of Urology, Tsuchiura Kyodo General Hospital, 1-1-4 Otsuno, Tsuchiura-shi, Ibaraki, 300-0028, Japan.
  • Department of Urology, Soka Municipal Hospital, 1-21-2 Soka, Soka-shi, Saitama, 340-8560, Japan.
  • Department of Urology, JA Toride Medical Hospital, 1-1-2 Hongo, Toride-shi, Ibaraki, 302-0022, Japan.
  • Department of Urology, Dokkyo Medical University Saitama Medical Center, 50-1-2 Minamikoshigaya, Koshigaya-shi, Saitama, 343-8555, Japan.

Zitieren

APA

Tanabe, K., Kobayashi, S., Maezawa, Y., Ishihara, K., Inoue, N., Izumi, K., Fujiwara, M., Toide, M., Yamamoto, T., Uehara, S., Araki, S., Inoue, M., Takazawa, R., Numao, N., Ohtsuka, Y., Tanaka, H., Yoshida, S., & Fujii, Y. (2024). Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02563-7

Vancouver

Tanabe K, Kobayashi S, Maezawa Y, Ishihara K, Inoue N, Izumi K, et al. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02563-7

BibTeX
@article{Tanabe2024,
  author = {Tanabe, Kenji and Kobayashi, Shuichiro and Maezawa, Yuya and Ishihara, Kensaku and Inoue, Naoki and Izumi, Keita and Fujiwara, Motohiro and Toide, Masahiro and Yamamoto, Takanobu and Uehara, Sho and Araki, Saori and Inoue, Masaharu and Takazawa, Ryoji and Numao, Noboru and Ohtsuka, Yukihiro and Tanaka, Hajime and Yoshida, Soichiro and Fujii, Yasuhisa},
  title = {Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02563-7}
}
Kostenlos starten →